Showing 4451-4460 of 5659 results for "".
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://practicaldermatology.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2468433/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. The goal of the rebrand is
- European Decentralized Regulatory Procedure Completed for Efinaconazolehttps://practicaldermatology.com/news/european-decentralized-regulatory-procedure-completed-efinaconazole/2468407/Almirall, S.A. announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of onychomycosis, under the trade name of Jublia®. The low binding affinity of efinaconazole topical to kerat
- New Study From Valisure Extends Previous Research on Benzoyl Peroxide Productshttps://practicaldermatology.com/news/study-benzene-risks-common-benzoyl-peroxide-products/2468369/A new study conducted by Valisure has raised concern about benzene contamination in benzoyl peroxide (BPO) drug products used for acne and rosacea treatment. Among 111 tested BPO products, 34% contained benzene concentrations exceeding the FDA's conditional limit of 2 parts per million (pp
- NEA Promotes Eczema Awareness Month in Octoberhttps://practicaldermatology.com/news/nea-promotes-eczema-awareness-month-october/2468331/The National Eczema Association (NEA) will present Eczema Awareness Month throughout October to spread awareness about living with eczema, the organization announced in a press release. This year's awareness campaign puts eczema on display with real, up-close photos of community members' f
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- Lebrikizumab Shows Sustained AD Control Up to 3 Years in More 80%https://practicaldermatology.com/news/lebrikizumab-shows-sustained-ad-control-3-years-more-80/2468297/More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to 3 years experienced sustained skin clearance with monthly maintenance dosing, Almirall
- Aerolase Art of Diversity Conference Continues Growinghttps://practicaldermatology.com/news/aerolase-art-diversity-conference-continues-growing/2468263/Aerolase’s third annual Art of Diversity conference in Jersey City, New Jersey, lived up to its name, with a diverse mix of practitioners and content that led to an engaging educational program. “The whole idea of the Art of Diversity for Skin Health is that there is an eclectic community
- Organon to Acquire VTAMA Maker Dermavanthttps://practicaldermatology.com/news/organon-acquire-vtama-maker-dermavant/2468226/Organon and Dermavant Sciences Ltd. announced that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant company whose product VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults was approv
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies
- Cord Blood Biomarkers and TEWL Predict Atopic Dermatitis in Infantshttps://practicaldermatology.com/news/cord-blood-biomarkers-and-tewl-predict-atopic-dermatitis-infants/2468171/A prospective study reports that elevated levels of CCL17 and IL-31 in cord blood, along with increased transepidermal water loss (TEWL) at the anterior cubital fossa, could help identify infants at higher risk of developing atopic dermatitis (AD) within their first year of life. The study